BridgeBio Pharma, Inc. (BBIO) [Rocket]

In millions, except per share items	Jun-30-23	Jun-05-23	Mar-31-23	Jun-30-22	Jun-05-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	8-K	10-Q	10-Q	8-K	10-Q	10-K	10-Q
Net income	-157.9	-160.7	-140.2	-9.9	-2.6	-196.4	0.0	0.0
Depreciation and amortization	1.6		1.6	1.6		1.9	-1.0	0.3
Stock-based compensation								-63.7
Change in working capital [+]	18.8		-28.7	34.8		-19.8	25.0	-4.1
Accounts receivable								1.0
Other current assets								-1.4
Accounts payable								-13.0
Accrued expenses	12.9		-8.6	10.7		-2.9	13.6	-4.2
Other	5.9		-20.1	24.1		-16.9	11.4	13.5
Other operating activities	24.1		22.9	-57.0		53.6	-157.9	-54.0
Cash from operations	-113.4		-144.3	-30.5		-160.6	-133.9	-121.6

Capital expenditures [+]	0.4		0.0	2.4		0.9	2.5	15.0
Purchases of property and equipment	0.4		0.0	2.4		0.9	2.5	15.0
Sales of property and equipment						10.0
Purchases of short-term investments, net	19.8			63.9		55.7	14.4	846.5
Purchases of short-term investments	19.8			63.9		55.7	14.4	1,085.4
Sales of short-term investments								-238.9
Other cash from investing	-16.1		12.3	83.4		72.0	4.9	-802.5
Cash from investing	4.1		12.3	149.7		138.6	21.8	59.0

Issuance of common stock, net	1.0		143.0				398.5	-143.2
Option exercises	0.1		2.0	0.1		1.1	2.3	3.1
Financing costs								32.1
Other cash from financing	-2.1		9.2	-20.7		0.9	-70.7	42.9
Cash from financing	-1.2		150.2	-20.8		-0.2	325.4	-135.5

Free cash flow	-112.9		-144.3	-28.1		-159.8	-131.4	-106.6
Per share (diluted)	($0.70)		($0.95)	($0.19)		($1.10)	($0.91)	($0.73)

Cash paid for interest	6.7		22.1	6.6		18.8	1.5	17.4